The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

More weight loss wasn’t the only advantage with Zepbound. People taking this drug also lost about 7 inches from their waistline, compared with roughly 5 inches with Wegovy.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study’s findings, what sets these drugs apart and ...

Is Zepbound or Wegovy better for weight loss? First-of-its-kind study offers answer. The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Wegovy led to significant weight loss but slightly less than Zepbound. In a 68-week trial, participants using Wegovy (2.4 mg) lost about 15% of their body weight.

Wegovy, like Zepbound, is FDA-approved for weight loss. Its main ingredient is semaglutide, which is also found in Ozempic , a medication that is approved by the FDA to treat Type 2 diabetes but ...

Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study's findings, what sets these drugs apart and how ...